Pular para o conteúdo
Merck
Todas as fotos(1)

Key Documents

Y0001426

Carvedilol for system suitability

European Pharmacopoeia (EP) Reference Standard

Sinônimo(s):

Carvedilol, 1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol, BM-14190

Faça loginpara ver os preços organizacionais e de contrato


About This Item

Fórmula empírica (Notação de Hill):
C24H26N2O4
Número CAS:
Peso molecular:
406.47
Número MDL:
Código UNSPSC:
41116107
ID de substância PubChem:
NACRES:
NA.24

grau

pharmaceutical primary standard

família API

carvedilol

fabricante/nome comercial

EDQM

aplicação(ões)

pharmaceutical (small molecule)

formato

neat

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

OC(COC1=CC=CC2=C1C3=C(C=CC=C3)N2)CNCCOC4=CC=CC=C4OC

InChI

1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3

chave InChI

OGHNVEJMJSYVRP-UHFFFAOYSA-N

Procurando produtos similares? Visita Guia de comparação de produtos

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Carvedilol for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Ações bioquímicas/fisiológicas

Cavedilol is a non-selective β-adrenergic blocker with α1 blocking activity. Carvedilol is used specifically for the treatment of heart failure and high blood pressure. It has been shown to improve left ventricular ejection fraction and may reduce mortality.

Embalagem

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Outras notas

Sales restrictions may apply.

produto relacionado

Nº do produto
Descrição
Preços

Pictogramas

Health hazardEnvironment

Palavra indicadora

Warning

Frases de perigo

Declarações de precaução

Classificações de perigo

Aquatic Chronic 2 - STOT RE 2

Órgãos-alvo

Liver,spleen,Uterus (including cervix),Adrenal gland

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable


Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Lamentamos, não temos COA para este produto disponíveis online no momento.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Péter Ferdinandy et al.
Pharmacological reviews, 66(4), 1142-1174 (2014-09-28)
Pre-, post-, and remote conditioning of the myocardium are well described adaptive responses that markedly enhance the ability of the heart to withstand a prolonged ischemia/reperfusion insult and provide therapeutic paradigms for cardioprotection. Nevertheless, more than 25 years after the
George L Bakris et al.
Reviews in cardiovascular medicine, 9(2), 96-105 (2008-07-29)
Few patients with hypertension meet recommended target blood pressure goals, and most hypertensive patients require at least 2 antihypertensive medications from different pharmacologic classes to adequately lower blood pressure. beta-Blockers are guideline-recommended for the treatment of hypertension with compelling indications.
Timothy Self et al.
The American journal of the medical sciences, 342(1), 56-61 (2011-02-05)
Cocaine-induced myocardial infarction (MI) is well documented. Current literature recommends avoiding beta-blockers in the acute care setting, but after discharge from the hospital, benefits of beta-blocker use may outweigh risks in patients with recent MI resulting from cocaine use. Cardioselective
Subhashis Chakraborty et al.
Expert opinion on drug metabolism & toxicology, 6(2), 237-250 (2010-01-16)
Carvedilol, a non-selective beta-blocker, has recently drawn attention because of its therapeutic benefits over other prescribed analogues for the treatment of cardiovascular diseases (CVDs). The present review attempts to present the clinical efficacy of carvedilol in comparison to other available
Adrian J Stanley et al.
Journal of hepatology, 61(5), 1014-1019 (2014-06-24)
Rebleeding after an initial oesophageal variceal haemorrhage remains a significant problem despite therapy with band ligation, non-selective β-blockers or a combination of these. Carvedilol is a vasodilating non-selective β-blocker with alpha-1 receptor and calcium channel antagonism. A recent study has

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica